找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cancer Therapeutic Targets; John L. Marshall Living reference work 20200th edition Anti-angiogenic Targets.HER2/EGFR Targets.Nuclear Rece

[復(fù)制鏈接]
查看: 32553|回復(fù): 64
樓主
發(fā)表于 2025-3-21 19:57:02 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Cancer Therapeutic Targets
編輯John L. Marshall
視頻videohttp://file.papertrans.cn/222/221211/221211.mp4
概述This reference work would be the first of its kind.Organized into major sections based on distinct aspects of cancer cell biology, each sub-section (galaxy) would provide comprehensive but brief 4-5 p
圖書封面Titlebook: Cancer Therapeutic Targets;  John L. Marshall Living reference work 20200th edition  Anti-angiogenic Targets.HER2/EGFR Targets.Nuclear Rece
描述.In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight...The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well..
出版日期Living reference work 20200th edition
關(guān)鍵詞Anti-angiogenic Targets; HER2/EGFR Targets; Nuclear Receptors; Hormone Receptors; Heme surface markers
doihttps://doi.org/10.1007/978-1-4614-6613-0
isbn_ebook978-1-4614-6613-0
The information of publication is updating

書目名稱Cancer Therapeutic Targets影響因子(影響力)




書目名稱Cancer Therapeutic Targets影響因子(影響力)學(xué)科排名




書目名稱Cancer Therapeutic Targets網(wǎng)絡(luò)公開度




書目名稱Cancer Therapeutic Targets網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cancer Therapeutic Targets被引頻次




書目名稱Cancer Therapeutic Targets被引頻次學(xué)科排名




書目名稱Cancer Therapeutic Targets年度引用




書目名稱Cancer Therapeutic Targets年度引用學(xué)科排名




書目名稱Cancer Therapeutic Targets讀者反饋




書目名稱Cancer Therapeutic Targets讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

1票 100.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 22:36:34 | 只看該作者
Anti-Apoptotic Bcl-2,hway. Approximately 25 members of the BCL-2 family have been grouped into three categories based on structure and function: (1) anti- apoptotic, (2) pro-apoptotic, and (3) BH3 only proteins. This chapter will focus on a family of five anti-apoptotic proteins: (1) BCL-2, (2) BCL-xL, (3) BCL-w, (4) MC
板凳
發(fā)表于 2025-3-22 03:24:05 | 只看該作者
地板
發(fā)表于 2025-3-22 05:50:43 | 只看該作者
5#
發(fā)表于 2025-3-22 08:46:03 | 只看該作者
Anti-Idiotype Antibodies,ed to as the “idiotype” (Id), is composed of the unique antigenic determinants in the variable regions of the clonal Ig heavy and light chains expressed by the tumor cells (Timmerman and Levy 2000). This protein target has the unusual nature of being unique in every B-cell cancer (Fig. 1). The human
6#
發(fā)表于 2025-3-22 16:47:42 | 只看該作者
7#
發(fā)表于 2025-3-22 18:43:26 | 只看該作者
APC,s a critical suppressor of cancer initiation. Individuals who inherit inactivating mutations in one allele of the . gene exhibit familial adenomatous polyposis (FAP) coli, an autosomal dominant syndrome characterized by the formation of a variety of benign lesions, particularly numerous adenomatous
8#
發(fā)表于 2025-3-22 23:20:50 | 只看該作者
9#
發(fā)表于 2025-3-23 02:00:46 | 只看該作者
10#
發(fā)表于 2025-3-23 05:51:23 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-10 23:37
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
永宁县| 贵南县| 崇阳县| 尼木县| 青阳县| 吴桥县| 云和县| 精河县| 清丰县| 衡阳市| 奈曼旗| 高平市| 通河县| 海门市| 阿拉善右旗| 延川县| 民乐县| 云南省| 织金县| 什邡市| 电白县| 诸城市| 镇江市| 墨竹工卡县| 凤翔县| 分宜县| 泽普县| 五指山市| 万年县| 明水县| 林周县| 山西省| 静安区| 衡南县| 汉寿县| 府谷县| 水城县| 体育| 东乌珠穆沁旗| 灵宝市| 泰顺县|